Sign in Subscribe
Pharmaceutical industry

Guilford Pharmaceuticals Receives FDA Clearance for GLIADEL Wafer

Strategic Insights

— 2 min read

Guilford Pharmaceuticals, a biopharmaceutical company, has made significant progress in the development of GLIADEL, a revolutionary treatment for malignant brain cancer. The company has received clearance from the U.S. Food and Drug Administration (FDA) for its Treatment IND application for GLIADEL, a polymer implant that releases cancer chemotherapeutic drug carmustine directly to the tumor site. This milestone is crucial, enabling patients with serious or life-threatening conditions to receive an investigational drug prior to FDA marketing approval. The development of GLIADEL marks a significant technological achievement for the company, with its manufacturing facility passing an FDA inspection and increasing capacity for commercial launch.

Key Takeaways:

  • Guilford Pharmaceuticals has received clearance from the FDA for its Treatment IND application for GLIADEL wafer, a treatment for malignant brain cancer.
  • GLIADEL is a totally new approach to the treatment of malignant brain cancer, releasing cancer chemotherapeutic drug carmustine directly to the tumor site.
  • The company will now focus its efforts on submitting a New Drug Application (NDA) to seek full marketing approval for GLIADEL.
  • As part of the review process for the Treatment IND, Guilford's manufacturing facility passed an FDA inspection.
  • According to the National Center for Health Statistics, approximately 20,000 surgical procedures for malignant brain tumors are performed annually in the United States.
  • Current standard therapy for malignant glioma consists of surgery to remove the tumor followed by radiation therapy and chemotherapy, with a poor prognosis even with the best available therapy.
  • Results from the Company's first Phase III clinical trial of GLIADEL demonstrated an increase in overall survival by approximately 35% compared to placebo, with no clinically important adverse effects observed.
  • A second Phase III clinical study has been completed in Europe and will be presented at the 11th International Conference on Brain Tumor Research and Therapy.

Statistics:

  • 20,000: The number of surgical procedures for malignant brain tumors performed annually in the United States (National Center for Health Statistics).
  • 35%: The increase in overall survival demonstrated by GLIADEL in a Phase III clinical trial compared to placebo.
  • 222: The number of patients enrolled in the Company's first Phase III clinical trial of GLIADEL.
  • 1995: The year the results of the Company's first Phase III clinical trial were published in The Lancet.
  • Nov 1: The date the results of a second Phase III clinical study in Europe will be presented at the 11th International Conference on Brain Tumor Research and Therapy.

Sources:

  • Guilford Pharmaceuticals Inc. (PRNewswire, 1995)
  • National Center for Health Statistics
  • The Lancet (April 1995)
  • 11th International Conference on Brain Tumor Research and Therapy (November 1)

Read more